Extracellular Matrix Proteomics: The mdx-4cv Mouse Diaphragm as a Surrogate for Studying Myofibrosis in Dystrophinopathy
P Dowling, S Gargan, M Zweyer, D Swandulla… - Biomolecules, 2023 - mdpi.com
The progressive degeneration of the skeletal musculature in Duchenne muscular dystrophy
is accompanied by reactive myofibrosis, fat substitution, and chronic inflammation. Fibrotic …
is accompanied by reactive myofibrosis, fat substitution, and chronic inflammation. Fibrotic …
Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy?
L Bello, EP Hoffman, E Pegoraro - Nature Reviews Neurology, 2023 - nature.com
Patients with Duchenne muscular dystrophy (DMD) show clinically relevant phenotypic
variability, despite sharing the same primary biochemical defect (dystrophin deficiency) …
variability, despite sharing the same primary biochemical defect (dystrophin deficiency) …
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials
S Kim, RJ Willcocks, MJ Daniels… - CPT …, 2023 - Wiley Online Library
Although regulatory agencies encourage inclusion of imaging biomarkers in clinical trials for
Duchenne muscular dystrophy (DMD), industry receives minimal guidance on how to use …
Duchenne muscular dystrophy (DMD), industry receives minimal guidance on how to use …
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies–Developing Potential Treatments for the …
C McDonald, E Camino, R Escandon… - Journal of …, 2024 - content.iospress.com
Background: Duchenne muscular dystrophy (DMD) and related dystrophinopathies are
neuromuscular conditions with great unmet medical needs that require the development of …
neuromuscular conditions with great unmet medical needs that require the development of …
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles
DY Yoon, MJ Daniels, RJ Willcocks, WT Triplett… - … of Pharmacokinetics and …, 2024 - Springer
The study aimed to provide quantitative information on the utilization of MRI transverse
relaxation time constant (MRI-T 2) of leg muscles in DMD clinical trials by developing …
relaxation time constant (MRI-T 2) of leg muscles in DMD clinical trials by developing …
Процена утицаја генетичких модификатора на клинички ток Дишенове мишићне дистрофије
A Kosać - Универзитет у Београду, 2023 - nardus.mpn.gov.rs
Увод: Дишенова мишићна дистрофија (ДМД) је најчешћа наследна болест мишића са
почетком у дечјем добу. Варијабилност клиничког тока ДМД делимично је објашњена …
почетком у дечјем добу. Варијабилност клиничког тока ДМД делимично је објашњена …
Процена Утицаја Генетичких Модификатора на Клинички Ток Дишенове Мишићне Дистрофије
AП Кпсаћ - 2023 - search.proquest.com
ПРОЦЕНА УТИЦАЈА ГЕНЕТИЧКИХ МОДИФИКАТОРА НА КЛИНИЧКИ ТОК ДИШЕНОВЕ МИШ
Page 1 УНИВЕРЗИТЕТ У БЕОГРАДУ МЕДИЦИНСКИ ФАКУЛТЕТ Aна П. Кпсаћ ПРОЦЕНА …
Page 1 УНИВЕРЗИТЕТ У БЕОГРАДУ МЕДИЦИНСКИ ФАКУЛТЕТ Aна П. Кпсаћ ПРОЦЕНА …